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Acute myeloid leukaemia (AML) is an aggressive haemato-
logical malignancy with a dismal long-term survival. Novel
therapeutic agents are therefore urgently required to
improve outcomes. AML is highly heterogeneous at the
molecular, cellular and clinical level, however common
themes have recently emerged, including transcriptional
dysregulation and alteration of epigenetic control. Indeed,
deep sequencing efforts have outlined recurrent mutations
in a number of epigenetic regulators in AML. This obser-
vation has potential clinical implications for, whilst the
genome is fixed, the epigenome is dynamic, making it a
potentially attractive target for therapeutics. This talk will
outline the clinical and biological background to AML and
will also provide context for targeting epigenetic readers.
The bromodomain and extra-terminal (BET) proteins
are a family of bromodomain-containing epigenetic read-
ers. They bind to acetylated lysines in histones and other
proteins and interact with a number of transcriptional
regulators during transcriptional commitment, initiation
and elongation. Recently, inhibitors of the protein-protein
interaction between BET proteins and acetylated lysines
have been developed, initially as anti-inflammatory
immunomodulators. We will outline our rationale for uti-
lising these inhibitors in a highly specific form of acute
leukaemia, mixed lineage leukaemia (MLL)-fusion leukae-
mias, and will briefly show published data justifying this
hypothesis. These data will outline the mechanism of
action of these inhibitors, demonstrating the removal
from chromatin of BET proteins and interacting tran-
scriptional complexes, leading to downregulation of tran-
scription at loci critical for leukaemogenesis. Finally,
preclinical studies demonstrating the efficacy of these
inhibitors in murine models, cellular models and patient
samples of MLL-fusion leukaemia will outline the efficacy
and clinical promise of these agents for this aggressive
form of leukaemia.
The majority of the talk will focus on unpublished
data investigating the extension of I-BET therapy to
other subtypes of AML. We will demonstrate that many
other subtypes of AML are sensitive to growth inhibi-
tion with I-BET. This sensitivity appears to be due to
the downregulation of a common transcriptional pro-
gramme across a number different AML subtypes. We
will show data predicting that this programme, along
with specific recurrent mutations, will form the basis of
predictive biomarkers of sensitivity and response to I-
BET therapy, thus informing clinical trials. We next
focused our attention on AML with mutations of the
nucleophosmin (NPM1) gene and describe the mechan-
ism underpinning the profound sensitivity of this com-
mon AML subtype. Finally, we will show evidence of
preclinical efficacy in murine, cellular and primary
patient material models of NPM1c AML.
At the end of the talk I will attempt to put these find-
ings into clinical context, briefly summarising the results
of BET inhibition in other haematological malignancies
and discussing an outline of plans for a phase I clinical
trail of BET inhibition in relapsed haem malignancies to
be carried out within the UK.
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